CA2341970A1 - Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees - Google Patents

Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees Download PDF

Info

Publication number
CA2341970A1
CA2341970A1 CA002341970A CA2341970A CA2341970A1 CA 2341970 A1 CA2341970 A1 CA 2341970A1 CA 002341970 A CA002341970 A CA 002341970A CA 2341970 A CA2341970 A CA 2341970A CA 2341970 A1 CA2341970 A1 CA 2341970A1
Authority
CA
Canada
Prior art keywords
group
radical
furan
unsubstituted
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341970A
Other languages
English (en)
Inventor
Thomas R. Bailey
Dorothy C. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Biologics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341970A1 publication Critical patent/CA2341970A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions et des procédés destinés au traitement et à la prévention des infections provoquées par des virus de la famille des Flaviviridae. Selon l'invention, on administre certains dérivés de rhodanine ou leurs analogues, les acides alcanoïques tri- et tétracycliques de rhodanine et les acides benzoïques de rhodanine s'étant avérés particulièrement efficaces.
CA002341970A 1998-08-21 1999-08-19 Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees Abandoned CA2341970A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US9747698P 1998-08-21 1998-08-21
US60/097,476 1998-08-21
US11321298P 1998-12-22 1998-12-22
US60/113,212 1998-12-22
US11932899P 1999-02-09 1999-02-09
US60/119,328 1999-02-09
US13558599P 1999-05-24 1999-05-24
US13558699P 1999-05-24 1999-05-24
US60/135,586 1999-05-24
US60/135,585 1999-05-24
PCT/US1999/018785 WO2000010573A1 (fr) 1998-08-21 1999-08-19 Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees

Publications (1)

Publication Number Publication Date
CA2341970A1 true CA2341970A1 (fr) 2000-03-02

Family

ID=27536838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341970A Abandoned CA2341970A1 (fr) 1998-08-21 1999-08-19 Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees

Country Status (10)

Country Link
EP (1) EP1128832A4 (fr)
JP (1) JP2002523371A (fr)
KR (1) KR20010099623A (fr)
CN (1) CN1325309A (fr)
AU (1) AU743411B2 (fr)
BR (1) BR9913157A (fr)
CA (1) CA2341970A1 (fr)
ID (1) ID27787A (fr)
IL (1) IL141456A0 (fr)
WO (1) WO2000010573A1 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103562T2 (tr) * 1999-06-10 2002-04-22 Warner-Lambert Company Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri
CA2383347A1 (fr) 1999-08-31 2001-03-08 Maxia Pharmaceuticals, Inc. Benzelidene-thiazolidinediones et leurs analogues, utilises dans le traitement du diabete
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP5260818B2 (ja) * 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
GB2376944A (en) * 2001-05-18 2002-12-31 Pantherix Ltd Polycyclic heterocyclic compounds and their therapeutic use
CA2448737C (fr) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
AU2002337765A1 (en) 2001-09-26 2003-04-07 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
AU2002352706A1 (en) * 2001-11-15 2003-06-10 Maxia Pharmaceuticals, Inc. N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
GB2387172A (en) * 2002-03-28 2003-10-08 Pantherix Ltd [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials
JP2005535593A (ja) * 2002-05-17 2005-11-24 キューエルティー インコーポレーティッド チアゾリジンジチオン誘導体の使用方法
PL211889B1 (pl) 2002-05-20 2012-07-31 Bristol Myers Squibb Co Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
CA2489433A1 (fr) 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibiteurs de la polymerase ns5b du vhc
BR0305259A (pt) 2002-07-01 2004-10-05 Upjohn Co Inibidores de hcv ns5b polimerase
FR2845000B1 (fr) * 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
BR0314943A (pt) * 2002-09-30 2005-08-02 Univ California Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
AU2003291024A1 (en) * 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
WO2005007141A2 (fr) * 2003-07-11 2005-01-27 Proteologics, Inc. Inhibiteurs de l'ubiquitine ligase et methodes associees
FR2858324A1 (fr) * 2003-07-30 2005-02-04 Centre Nat Rech Scient Nouveaux composes antibiotiques, compositions pharmaceutiques les contenant et leurs utilisations
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
US7566732B2 (en) 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents
US7026339B2 (en) 2003-11-07 2006-04-11 Fan Yang Inhibitors of HCV NS5B polymerase
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
UA86962C2 (en) 2004-02-20 2009-06-10 Бёрингер Ингельхайм Интернациональ Гмбх Viral polymerase inhibitors
RS50815B (sr) 2004-02-24 2010-08-31 Japan Tobacco Inc. Kondenzovana heterotetraciklična jedinjenja i njihova upotreba kao inhibitora hcv polimeraza
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
CN101189230A (zh) 2005-05-04 2008-05-28 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
CA2608821A1 (fr) * 2005-06-15 2006-12-28 Shibo Jiang Compositions antivirales comprenant des phenyl-furanes heterocycliques substitues et composes associes
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CN101437824B (zh) * 2006-05-04 2013-03-13 肝炎与病毒研究所 用于慢性肝炎病毒治疗的乙型肝炎病毒抗原分泌的抑制剂
RS51643B (en) 2006-10-10 2011-10-31 Medivir Ab. INHIBITOR HCV NUKLEOZIDA
WO2008082537A2 (fr) 2006-12-19 2008-07-10 The General Hospital Corporation Composés pour moduler l'intégrine cd11b/cd18
AU2008271116B2 (en) 2007-06-29 2012-09-20 Gilead Sciences, Inc. Antiviral compounds
CN101801925A (zh) 2007-06-29 2010-08-11 吉里德科学公司 抗病毒组合物
CN101990534A (zh) 2007-11-01 2011-03-23 Uab研究基金会 治疗和预防病毒感染
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
US7947717B2 (en) 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Ｈｃｖ ｎｓ5ａ의 억제제
BRPI0922366B8 (pt) 2008-12-03 2021-05-25 Presidio Pharmaceuticals Inc composto, composição farmacêutica e uso de um composto
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
KR20120104239A (ko) 2009-11-14 2012-09-20 에프. 호프만-라 로슈 아게 Ｈｃｖ 치료에 대한 신속한 반응을 예측하기 위한 바이오마커
WO2011067195A1 (fr) 2009-12-02 2011-06-09 F. Hoffmann-La Roche Ag Biomarqueurs pour prédire une réponse soutenue à un traitement du vhc
AU2010336027A1 (en) * 2009-12-23 2012-07-19 Auckland Uniservices Limited Compounds, preparations and uses thereof
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
KR101159000B1 (ko) * 2010-06-18 2012-06-21 (주) 에빅스젠 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
US9255088B2 (en) 2010-08-11 2016-02-09 The Regents Of The University Of California Premature-termination-codons readthrough compounds
WO2012123298A1 (fr) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Composés antiviraux
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
KR101621181B1 (ko) 2011-10-10 2016-05-13 에프. 호프만-라 로슈 아게 항바이러스성 화합물
CN103987723B (zh) 2011-12-16 2017-03-01 弗·哈夫曼-拉罗切有限公司 Hcv ns5a 的抑制剂
ES2626484T3 (es) 2011-12-20 2017-07-25 Riboscience Llc Derivados nucleosídicos 4'-azido-3'-fluoro-sustituidos como inhibidores de la replicación del ARN de VHC
EP2794629B1 (fr) 2011-12-20 2017-05-24 Riboscience LLC Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
WO2013124335A1 (fr) 2012-02-24 2013-08-29 F. Hoffmann-La Roche Ag Composés antiviraux
WO2013142346A1 (fr) 2012-03-23 2013-09-26 The Regents Of The University Of California Composés de translecture de codons de terminaison prématurés
WO2013159082A1 (fr) 2012-04-20 2013-10-24 Adhaere Pharmaceuticals, Inc. Composés et méthodes pour la régulation d'intégrines
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
BR112015017414A2 (pt) 2013-01-23 2017-07-11 Hoffmann La Roche derivados de triazol antivirais
CN105008350B (zh) 2013-03-05 2018-05-08 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
SG11201509424VA (en) 2013-05-16 2015-12-30 Riboscience Llc 4'-fluor0-2'-methyl substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
KR20200056420A (ko) 2017-09-21 2020-05-22 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
KR101893988B1 (ko) * 2018-05-16 2018-08-31 (주)에빅스젠 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물
TW202348228A (zh) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 病毒組合療法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909467A (en) * 1958-07-09 1959-10-20 Us Vitamin Pharm Corp 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione
US3888984A (en) * 1972-03-13 1975-06-10 Lilly Industries Ltd Oxazole and imidazole derivatives as antifungal agents
AU6610081A (en) * 1980-01-24 1981-07-30 Senju Pharmaceutical Co., Ltd. Thiazolidine derivatives
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
MX9302578A (es) * 1992-05-01 1994-08-31 Commw Scient Ind Res Org Agentes antivirales.
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
DE19645974C1 (de) * 1996-11-07 1998-08-13 Andreas Johannes Kesel (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methylen]-2-thioxo-4- thiazolidinon, Verfahren zu dessen Herstellung und Verwendung

Also Published As

Publication number Publication date
ID27787A (id) 2001-04-26
AU5570299A (en) 2000-03-14
CN1325309A (zh) 2001-12-05
BR9913157A (pt) 2001-05-15
EP1128832A1 (fr) 2001-09-05
WO2000010573A1 (fr) 2000-03-02
JP2002523371A (ja) 2002-07-30
IL141456A0 (en) 2002-03-10
EP1128832A4 (fr) 2003-03-05
KR20010099623A (ko) 2001-11-09
AU743411B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
AU743411B2 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
US6316492B1 (en) Methods for treating or preventing viral infections and associated diseases
AU751201B2 (en) Methods for treating or preventing viral infections and associated diseases
EP1567112B1 (fr) THIAZOLIDIN-4-ONES POUR INHIBER LES PROTÉINES hYAK3
US6545009B1 (en) Retinoid-related receptor function regulating agent
WO2002051849A1 (fr) Inhibiteurs cdk4
CA2574354A1 (fr) Derives imidazole et thiazole utilises comme agents antiviraux
EP0513379A1 (fr) Derive de 2-arylthiazole et composition pharmaceutique contenant ce derive
US20020052396A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
KR20080079324A (ko) 11 베타-에이치에스디1 억제제로서 티아졸
KR101312198B1 (ko) 아데노신 ａ１수용체 길항제로서 신규 화합물
JP2004523540A (ja) 形質転換成長因子β（ＴＧＦ−β）阻害剤としての２−アミノ−４−（ピリジン−２−イル）−チアゾール誘導体
EP1419770A1 (fr) Agent d'acc l ration de l'expression de apo ai
KR20050057415A (ko) 전환성장인자(ｔｇｆ) 억제제로서의 신규한 싸이아졸 및 옥사졸 화합물
WO2007143597A2 (fr) Composés organiques
JP2005508931A (ja) 抗増殖性化合物としてのｎ−（４−（４−メチルチアゾール−５−イル）ピリミジン−２−イル）−ｎ−フェニルアミン類
EP2225235A2 (fr) Dérivés d'éther et de thioéther hétérocycliques et procédés d'utilisation de ceux-ci
US20030195213A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2007133211A1 (fr) Composés de quinolone et coumarine 3,4-disubstitués
JP2004524302A (ja) ＴＧＦ−β阻害剤としてのチアゾールアミンおよびその使用
CN101018785A (zh) 噻唑啉酮2－取代的喹啉
JPH11302280A (ja) チアゾリジン誘導体、およびその誘導体を有効成分とする医薬
JP2022542390A (ja) ジヒドロピリミジン誘導体及びｈｂｖ感染又はｈｂｖ誘導性疾患の処置におけるその使用
JP2005035998A (ja) ビスラクトン誘導体及びその医薬組成物としての使用
MXPA01003030A (en) Methods for treating or preventing viral infections and associated diseases

Legal Events

Date Code Title Description
FZDE Discontinued